Citigroup Lowers Stryker Price Target as RBC Capital Maintains Sell Rating on Pfizer

Analysts have issued updated ratings and price targets for major players in the healthcare and medical technology sectors, specifically focusing on Stryker and Pfizer. Citigroup lowered its price target for Stryker Corp (SYK) to $385 from $420, while maintaining a "Buy" rating on the stock. Meanwhile, RBC Capital reiterated its "Sell" rating on Pfizer (PFE) with a target price of $25, reflecting a continued bearish outlook. These adjustments come as analysts assess company-specific performance and broader market conditions ahead of the Q1 2026 earnings season. While the target cut for Stryker suggests a more cautious valuation, the retained "Buy" rating indicates underlying confidence in the company's growth. Conversely, Pfizer continues to face skepticism from analysts, as evidenced by the maintained underperform rating.